🚨 New Pharmacotherapy for Obstructive Sleep Apnoea 🌙💊 In a landmark Phase 2 trial published in The Lancet, sultiame— a carbonic anhydrase inhibitor—showed dose-dependent reduction in AHI and improved nocturnal oxygenation in adults with moderate–severe OSA.   💡 Key insights: • 298 participants across 5 European countries • 200 mg daily delivered the best efficacy-to-tolerability balance • Benefits most notable in sleepy phenotypes (ESS >10) • Mild, dose-related paraesthesia most common AE   🔬 A promising step toward precision sleep medicine and pharmacologic options for patients who struggle with CPAP.   🌬️ Better breathing by night → brighter cognition by day.   📖 Lancet, 2025 — FLOW Study (Randerath et al.)

Ver todos los episodios